Dextromethorphan Hydrobromide; Quinidine Sulfate Patent Expiration
Dextromethorphan Hydrobromide; Quinidine Sulfate is Used for managing symptoms of pseudobulbar affect. It was first introduced by Otsuka America Pharmaceutical Inc
Dextromethorphan Hydrobromide; Quinidine Sulfate Patents
Given below is the list of patents protecting Dextromethorphan Hydrobromide; Quinidine Sulfate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nuedexta | US7659282 | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | Aug 13, 2026 | Otsuka America Pharm |
| Nuedexta | US8227484 | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
Jul 17, 2023
(Expired) | Otsuka America Pharm |
| Nuedexta | USRE38115 | Dextromethorphan and an oxidase inhibitor for treating intractable conditions |
Jan 26, 2016
(Expired) | Otsuka America Pharm |
Dextromethorphan Hydrobromide; Quinidine Sulfate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List